ORIENTBIO, Inc. Statistics
Want to see KR:002630 full AI Analyst Report?
ORIENTBIO, Inc. (002630) Stock Statistics & Valuation Metrics
Total Valuation
ORIENTBIO, Inc. has a market cap or net worth of KRW 35.76B. The enterprise value is KRW 68.05B.
- Market Cap
- KRW 35.76B
- Enterprise Value
- KRW 68.05B
Share Statistics
ORIENTBIO, Inc. has 29,645,752 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 29,645,752
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
ORIENTBIO, Inc.’s return on equity (ROE) is -0.07 and return on invested capital (ROIC) is -5.74%.
- Return on Equity (ROE)
- -0.07
- Return on Assets (ROA)
- -0.06
- Return on Invested Capital (ROIC)
- -5.74%
- Return on Capital Employed (ROCE)
- -0.06
- Revenue Per Employee
- 238.04M
- Profits Per Employee
- -36.54M
- Employee Count
- 125
- Asset Turnover
- 0.36
- Inventory Turnover
- 10.59
Valuation Ratios
The current PE Ratio of ORIENTBIO, Inc. is 15.48. ORIENTBIO, Inc.’s PEG ratio is 0.06.
- PE Ratio
- 15.48
- PS Ratio
- 1.25
- PB Ratio
- 0.50
- Price to FCF
- 6.07
- Price to Operating Cash Flow
- 5.04
- PEG Ratio
- 0.06
Income Statement
In the last 12 months, ORIENTBIO, Inc. had revenue of 29.75B and earned -4.57B in profits. Earnings per share was -154.06.
- Revenue
- 29.75B
- Gross Profit
- 3.96B
- Operating Income
- -4.44B
- Pretax Income
- -4.57B
- Net Income
- -4.57B
- EBITDA
- -2.24B
- Earnings Per Share (EPS)
- -154.06
Cash Flow
In the last 12 months, operating cash flow was 7.09B and capital expenditures -1.20B, giving a free cash flow of 5.90B billion.
- Operating Cash Flow
- 7.09B
- Free Cash Flow
- 5.90B
- Free Cash Flow per Share
- 198.87
Dividends & Yields
ORIENTBIO, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 16.48%
- Earnings Yield
- 6.46%
Stock Price Statistics
- Beta
- -0.08
- 52-Week Price Change
- -53.86%
- 50-Day Moving Average
- 1559.56
- 200-Day Moving Average
- 1924.97
- Relative Strength Index (RSI)
- 37.93
- Average Volume (3m)
- 72.10K
Important Dates
ORIENTBIO, Inc. upcoming earnings date is Feb 15, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 16, 2026
- Next Earnings Date
- Feb 15, 2027
- Ex-Dividend Date
- ―
Financial Position
ORIENTBIO, Inc. as a current ratio of 7.82, with Debt / Equity ratio of 2.82%
- Current Ratio
- 7.82
- Quick Ratio
- 7.39
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 1.74
- Interest Coverage Ratio
- -34.60
Taxes
In the past 12 months, ORIENTBIO, Inc. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
ORIENTBIO, Inc. EV to EBITDA ratio is 4.82, with an EV/FCF ratio of 4.41.
- EV to Sales
- 0.91
- EV to EBITDA
- 4.82
- EV to Free Cash Flow
- 4.41
- EV to Operating Cash Flow
- 3.67
Balance Sheet
ORIENTBIO, Inc. has KRW 38.08B in cash and marketable securities with KRW 1.19B in debt, giving a net cash position of KRW 36.89B billion.
- Cash & Marketable Securities
- KRW 38.08B
- Total Debt
- KRW 1.19B
- Net Cash
- KRW 36.89B
- Net Cash Per Share
- KRW 1,244.29
- Tangible Book Value Per Share
- KRW 2,435.12
Margins
Gross margin is 20.49%, with operating margin of 8.89%, and net profit margin of 8.07%.
- Gross Margin
- 20.49%
- Operating Margin
- 8.89%
- Pretax Margin
- 8.07%
- Net Profit Margin
- 8.07%
- EBITDA Margin
- 18.82%
- EBIT Margin
- 10.70%
Analyst Forecast
The average price target for ORIENTBIO, Inc. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -3.47%
- EPS Growth Forecast
- 98.69%
Scores
- Smart Score
- ―
- AI Score
- 57

